Related Experiment Videos
What does the future hold for ACE inhibitors?
1Wythenshawe Hospital Wythenshawe, Manchester, UK.
Insights
Hypertension increases myocardial infarction (MI) risk more than stroke. Angiotensin-converting enzyme (ACE) inhibitors offer benefits beyond blood pressure reduction, improving overall cardiovascular health in hypertensive patients.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Myocardial infarction (MI) is the leading cause of death in hypertensive patients, significantly more common than stroke.
- While lowering blood pressure reduces stroke incidence, its effect on MI is less pronounced, suggesting other cardiovascular risk factors are involved.
- Traditional antihypertensive agents may not adequately address co-existing risk factors like obesity, lipid disorders, and insulin resistance, and some may even exacerbate them.
Purpose of the Study:
- To evaluate the role of various antihypertensive agents in managing hypertension and associated cardiovascular risks.
- To identify antihypertensive medications that offer benefits beyond blood pressure reduction, addressing the broader coronary risk profile.
- To explore the specific advantages of ACE inhibitors in improving quality of life and cardiovascular outcomes in hypertensive individuals.
Main Methods:
- Comparative analysis of antihypertensive drug classes (beta-blockers, diuretics, ACE inhibitors) regarding their impact on stroke and MI incidence.
- Assessment of the effects of these agents on associated cardiovascular risk factors and patient quality of life.
- Review of clinical evidence supporting the use of ACE inhibitors for specific cardiovascular conditions and risk factor modification.
Main Results:
- Lowering blood pressure significantly reduces stroke but has a limited impact on MI rates.
- Certain antihypertensive drugs, like potassium-losing diuretics, may increase the risk of sudden death and MI in some patient groups.
- ACE inhibitors demonstrate potential for improving quality of life, positively impacting coronary risk factors, and offering benefits in conditions like left ventricular hypertrophy and post-MI remodeling.
Conclusions:
- There is a need for antihypertensive agents that are effective, well-tolerated, and improve the overall coronary risk profile.
- ACE inhibitors show promise as a preferred treatment option due to their multifaceted benefits, including improving cardiovascular risk factors and patient quality of life.
- ACE inhibitors offer significant advantages in managing hypertensive patients, particularly those with impaired left ventricular function, hypertrophy, and those at risk of adverse cardiac remodeling post-MI.
Abstract:
The most common cause of death in hypertensive patients is myocardial infarction (MI), being three times more common than stroke. Lowering raised BP results in 40% fewer strokes, but only 14% fewer MIs. This may be because other coronary risk factors that often accompany hypertension (e.g. obesity, lipid and thrombotic disturbances, insulin insensitivity, increased plasma renin activity and increased sympathetic activity) are either unaffected or exacerbated by some of the traditional antihypertensive agents. Some of these risk factors show a diurnal rhythm peaking at 07.00-10.00 hours, thus this time constitutes a 'vulnerable period' for sudden death or death from MI. beta-blockers and diuretics have been effective in preventing stroke, but diuretics (at least potassium-losing diuretics) might actually increase the incidence of sudden death and MI in young to middle-aged hypertensive subjects (though elderly patients may benefit). Quality of life can be impaired by some beta-blockers, and diuretics can cause metabolic upset and male impotence. Thus, antihypertensive agents that are not only effective and well tolerated but are beneficial to the broader coronary risk profile are desirable. ACE inhibitors should prove particularly useful in terms of: good quality of life; non-exacerbation or improvement of coronary risk factors; treating patients with impaired left ventricular function; reversing left ventricular hypertrophy and vascular wall hypertrophy, thus improving coronary flow reserve; atheroma regression; renal protection, particularly in diabetes; and prevention or regression of LV dilatation (remodelling) following MI.